Roy A. Whitfield

Co-Founder at Incyte Corp.

Roy A. Whitfield

Roy A. Whitfield

Co-Founder at Incyte Corp.

Overview
Career Highlights

Incyte Corp.

RelSci Relationships

366

Number of Boards

7

Birthday

1953

Age

65

Relationships
RelSci Relationships are individuals Roy A. Whitfield likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Station X, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Nektar Therapeutics

Relationship likelihood: Strong

Co-Founder at Invitae Corp.

Relationship likelihood: Strong

Co-Founder at Station X, Inc.

Relationship likelihood: Strong

Founder at Numenor Ventures LLC

Relationship likelihood: Strong

Co-Founder at Quanterix Corp.

Relationship likelihood: Strong

Director at ProteinSimple, Inc.

Relationship likelihood: Strong

Executive Chairman at Pelikan Technologies, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Illumina, Inc.

Relationship likelihood: Strong

Former President & Chief Executive Officer at Illumina, Inc.

Relationship likelihood: Strong

Paths to Roy A. Whitfield
Potential Connections via
Relationship Science
You
Roy A. Whitfield
Co-Founder at Incyte Corp.
Education
BS in Mathematics

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

MBA

The Stanford Graduate School of Business has built an international reputation based on its innovative programs, which include: Two-year MBA Program, designed to educate business leaders One-year Stanford Sloan Master’s Program for mid-career executives PhD Program for future academics Executive Education programs for experienced managers Faculty research program Academic programs, including the two-year MBA, the 12-month Sloan Master's Program, and the PhD program, create a transformational student experience that reflects the tagline: Change lives. Change organizations. Change the world. Today the state-of-the-art Knight Management Center complex enables Stanford's innovative, globalized MBA curriculum, offering flexible classroom spaces for hands-on experiential learning small-group leadership labs, and team-based learning. It engages faculty and students across Stanford University, as well as alumni, global executives, and the broader world community.

Career History
Advisor
Prior - 2008

InterWest Partners focuses on early-stage investments in life sciences and information technology companies. Within the life sciences sector, the firm invests in a range of early-stage opportunities including the funding of preclinical companies with great potential. They also consider investing in or starting new companies around clinical or commercial stage assets. Within the information technology sector, InterWest looks for early-stage companies with near-term ROI-based value propositions. They favor investments in development-stage companies. Investments average $10 million to $15 million over the life of a company. InterWest serves as the lead investor in the majority of their investments.

Co-Founder
1991 - 2014

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Head-Operations & Business Development
1984 - 1989
Boards & Committees
Member, Board of Directors
2000 - Current

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Director
Current

Station X, Inc. develops software products for scientists and clinicians. It provides products to scientists who work with large-scale human genome information in either a research or clinical setting, enabling them to extract maximal biological meaning from complex genomic data. The company was founded by Richard D. Goold, Tod M. Klingler and Andrew R. MacBride in August 2010 and is headquartered in San Francisco, CA.

Director
Prior - 2010

Sciona, Inc. provides health and nutrition recommendations. It researches and develops DNA screens for common gene variants that affect an individual's response to food, medications and the environment. These genetic screens serve as the basis for providing personalized advice to consumers. The company was founded by Rosalynn Gill-Garrison and Gareth Roberts on June 8, 2000 and is headquartered in Boulder, CO.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Roy A. Whitfield. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Roy A. Whitfield's profile does not indicate a business or promotional relationship of any kind between RelSci and Roy A. Whitfield.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/roy-a-whitfield-3228335
  • https://relationshipscience.com/person/roy-a-whitfield-3228335